King Pharmaceuticals, Inc. and Acura Pharmaceuticals, Inc. today announced that the Companies plan to develop and submit a New Drug Application (NDA) for Acurox(R) (oxycodone HC1) Tablets (without niacin) intended to relieve moderate to severe pain and introduce limits and impediments to potential abuse via nasal snorting of crushed tablets and intravenous injection of dissolved tablets.
Interested in Monitoring? Call 877-596-2224
Current Customers Call 877-296-6465
Patients & Other Questions Call 877-643-6179